The Latest Cardiac and Vascular News
SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship to patient baseline ejection […]
Company Plans to Meet with FDA in Q1 to Discuss Results of GALACTIC-HF Enrollment Completed in Cohort 2 of REDWOOD-HCM; Results Expected Mid-Year Company Provides 2021 Financial Guidance; More Than Two Years of Cash Runway SOUTH SAN FRANCISCO, Calif., Feb. […]
Appointment Adds to Board Expertise in Commercial Development and Market Access as Company Prepares for Further Corporate Development SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Muna Bhanji has been appointed to the […]
Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its third annual Communications Fellowship Grant program, intended to […]
Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Inc. (Nasdaq: CYTK) today announced that the first patient has been dosed in Cohort 2 of REDWOOD-HCM (Randomized Evaluation of Dosing With […]
Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and Licensing SOUTH SAN FRANCISCO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) announced that Amgen Inc. […]
Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive Hypertrophic Cardiomyopathy with No Dose Interruptions Due to Left Ventricular Ejection Fraction Below 50% SOUTH SAN FRANCISCO, Calif., Dec. 09, […]
Supplemental Analyses of Primary Composite Endpoint Further Demonstrate Effect of Omecamtiv Mecarbil In Patients with Lower Ejection Fraction SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), […]
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2020 it granted stock options to purchase an aggregate of 62,850 shares of common stock to six new employees whose […]
Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event […]
![Life Molecular Imaging Secures FDA Fast Track Designation for [18F]Florbetaben in Diagnosing Cardiac AL and ATTR Amyloidosis](https://cardiacvascularnews.com/wp-content/uploads/2025/01/Life-molecular-imaging-e1737489511884-90x60.png)